PRODUCT INFORMATION



cRIPGBM

Item No. 38115

CAS Registry No.: 2361988-77-2

Formal Name: 3-[(4-fluorophenyl)methyl]-


2-methyl-4,9-dioxo-1-

(phenylmethyl)-1H-naphth[2,3-d]

imidazolium, monochloride

 $C_{26}H_{20}FN_2O_2 \bullet CI$ MF:

FW: 446.9 **Purity:** ≥98% Supplied as: A solid Storage: -20°C Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

cRIPGBM is supplied as a solid. A stock solution may be made by dissolving the cRIPGBM in the solvent of choice, which should be purged with an inert gas. cRIPGBM is soluble in DMSO and slightly soluble in acetonitrile.

cRIPGBM is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

cRIPGBM is an active metabolite of the anticancer prodrug RIPGBM (Item No. 27860).¹ It is formed from RIPGBM selectively in GBM1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) over primary human lung fibroblasts (HLFs). cRIPGBM induces apoptosis in GBM1 cells (EC_{50} = 68 nM). It binds to receptorinteracting serine/threonine kinase 2 (RIPK2) in a cell-free assay, as well as inhibits the interaction between RIPK2 and TGF-β-activated kinase 1 (TAK1) and promotes the interaction between RIPK2 and caspase-1 in GBM1 cells.

Reference

1. Lucki, N.C., Villa, G.R., Vergani, N., et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc. Natl. Acad. Sci. USA 116(13), 6435-6440 (2019).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 02/15/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM